Literature DB >> 13094099

ISONIAZID in combination with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis; fifth report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee.

.   

Abstract

Entities:  

Keywords:  NICOTINIC ACID ISOMERS/therapeutic use; PARA-AMINOSALICYLIC ACID/therapeutic use; STREPTOMYCIN/therapeutic use; TUBERCULOSIS, PULMONARY/therapy

Mesh：

Substances：

Year:  1953        PMID： 13094099      PMCID： PMC2030022     

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  7 in total

Review 1.  The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.

Authors:  Ahmed A Abulfathi; Peter R Donald; Kim Adams; Elin M Svensson; Andreas H Diacon; Helmuth Reuter
Journal:  Br J Clin Pharmacol       Date:  2020-06-21       Impact factor: 4.335

2.  Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Lizanne de Kock; Sherwin K B Sy; Bernd Rosenkranz; Andreas H Diacon; Kim Prescott; Kenneth R Hernandez; Mingming Yu; Hartmut Derendorf; Peter R Donald
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

3.  Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis.

Authors:  Yves Kibleur; Hervé Brochart; Hendrik S Schaaf; Andre H Diacon; Peter R Donald
Journal:  Clin Drug Investig       Date:  2014-04       Impact factor: 2.859

4.  Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.

Authors:  Anneke C Hesseling; Paolo Denti; Louvina E van der Laan; Anthony J Garcia-Prats; H Simon Schaaf; Maxwell Chirehwa; Jana L Winckler; Jun Mao; Heather R Draper; Lubbe Wiesner; Jennifer Norman; Helen McIlleron; Peter R Donald
Journal:  Antimicrob Agents Chemother       Date:  2022-05-04       Impact factor: 5.938

Review 5.  Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Ronald G Hall; Richard D Leff; Tawanda Gumbo
Journal:  Pharmacotherapy       Date:  2009-12       Impact factor: 4.705

6.  Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum.

Authors:  Peter Ankomah; Bruce R Levin
Journal:  PLoS Pathog       Date:  2012-01-12       Impact factor: 6.823

Review 7.  Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium.

Authors:  Surendra K Sharma; Alladi Mohan
Journal:  Indian J Med Res       Date:  2013-03       Impact factor: 2.375
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.